Bacterial infections in patients hospitalized with COVID-19

Víctor Moreno-Torres · Carmen de Mendoza · Sara de la Fuente · Enrique Sánchez · María Martínez-Urbistondo · Jesús Herráiz · Andrea Gutiérrez · Ángela Gutiérrez · Carlos Hernández · Alejandro Callejas · Carmen Maínez · Ana Royuela · Valentín Cuervas-Mons on behalf of the Puerta de Hierro COVID-19 working group

Received: 19 May 2021 / Accepted: 2 August 2021 / Published online: 18 August 2021 © The Author(s) 2021

Abstract
Bacterial infections may complicate the course of COVID-19 patients. The rate and predictors of bacterial infections were examined in patients consecutively admitted with COVID-19 at one tertiary hospital in Madrid between March 1st and April 30th, 2020. Among 1594 hospitalized patients with COVID-19, 135 (8.5%) experienced bacterial infectious events, distributed as follows: urinary tract infections (32.6%), bacteremia (31.9%), pneumonia (31.8%), intra-abdominal infections (6.7%) and skin and soft tissue infections (6.7%). Independent predictors of bacterial infections were older age, neurological disease, prior immunosuppression and ICU admission \( (p < 0.05) \). Patients with bacterial infections who more frequently received steroids and tocilizumab, progressed to lower Sap02/FiO2 ratios, and experienced more severe ARDS \( (p < 0.001) \). The mortality rate was significantly higher in patients with bacterial infections as compared to the rest (25% vs 6.7%, respectively; \( p < 0.001) \). In multivariate analyses, older age, prior neurological or kidney disease, immunosuppression and ARDS severity were associated with an increased mortality \( (p < 0.05) \) while bacterial infections were not. Conversely, the use of steroids or steroids plus tocilizumab did not confer a higher risk of bacterial infections and improved survival rates. Bacterial infections occurred in 8.5% of patients hospitalized with COVID-19 during the first wave of the pandemic. They were not independently associated with increased mortality rates. Baseline COVID-19 severity rather than the incidence of bacterial infections seems to contribute to mortality. When indicated, the use of steroids or steroids plus tocilizumab might improve survival in this population.

Keywords COVID-19 pneumonia · Bacterial infections · Steroids

Abbreviations
ARDS Acute respiratory distress syndrome
DTR Difficult- to-treat resistance

Introduction
Already in the middle of 2021, the SARS-CoV-2 infection continues, being the largest health problem worldwide [1]. Since its first outbreak in December 2019 and the official consideration as a pandemic by the WHO, the disease has spread through the world affecting practically every community. COVID-19 disease occurs in several phases in which
some patients require hospitalization due to acute respiratory distress (ARDS) after the so-called cytokine storm or cytokine release syndrome [2]. Among different therapeutic options, treatment with corticosteroids and tocilizumab has been widely used with conflicting results for the latter [3–5]. In addition, the use of these immunosuppressants could increase the risk of secondary infections [6, 7]; not to forget that respiratory viral infections may also predispose to bacterial [8].

In the present study, our objective was to describe and analyze the prevalence of bacterial infections and the main risk factors for infections, other than SARS-CoV-2, in patients admitted due to COVID-19 pneumonia during the first period of the pandemic. We analyzed the rate of patients with bacterial infections as well as their impact on COVID-19 morbidity and mortality. Knowing the characteristics of bacterial infections in patients with COVID-19 could help us optimize therapeutic options, and corticosteroids and/or antibiotic therapy use in patients at risk.

Patients and methods

Study design and patients

This retrospective observational cohort study was performed at Hospital Puerta de Hierro-Majadahonda, a large tertiary university hospital located in Madrid, one of the most affected regions by COVID-19 during the first wave. The study population consisted of adult patients who were admitted because of interstitial pneumonia due to suspected or confirmed SARS-CoV-2 between March 1st and April 30th, coinciding with lockdown and the first pandemic wave. According to this, both RT-PCR confirmed SARS-CoV-2 infection and suspected SARS-CoV-2 interstitial pneumonia (in the absence of other causes) were included. Follow-up continued to June 30th, 2020. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and was approved by the hospital’s Research Ethics Commission. All patients were requested their consent to register their clinical information into a database for epidemiological studies.

Local treatment protocol

During the first pandemic wave, immunosuppressive and antibiotic therapy was protocolized in our center. All patients with interstitial pneumonia received azithromycin and hydroxychloroquine during 3 and 5 days, respectively. Lopinavir/ritonavir was used if the patient presented hypoxemia during the first 10 days after symptom onset while interferon-beta (IFN-β) use was determined by the presence of respiratory insufficiency. Steroids and/or tocilizumab were considered in case of ARDS 7 days after symptom onset and in the absence of data suggestive of bacterial superinfection. Empirical antibiotic therapy with cephalosporins in addition to azithromycin relied on the physician’s criteria for each situation.

Data collection and outcomes

Electronic medical records for all hospital admitted patients with COVID-19 pneumonia were reviewed. The main demographics, the baseline comorbidities including immunosuppression and immunosuppressive treatment, microbiological tests (respiratory samples, urinary antigen test, blood, urine and other sites cultures depending on the foci), immunosuppressive treatment received to treat COVID-19 ARDS and outcomes, were collected directly from the electronic medical records. All data were registered by a primary reviewer and subsequently checked by at least two senior physicians.

Definitions

Immunosuppression was defined either as the presence of hematological disease (active lymphoproliferative, myeloproliferative disorders or bone marrow transplantation), solid organ transplantation, active and disseminated solid organ neoplasm or any condition, including autoimmune disease (e.g., Systemic Lupus Erythematosus, Sjögren Syndrome or Inflammatory Bowel Disease…) that had required immunosuppressive treatment for at least 3 months. Immunosuppressive treatment was considered when the patient was either receiving active treatment at the time of admission, including equivalent doses of prednisone above 5 mg, or had received chemotherapy or immunotherapy 6 months before disease onset.

Acute Respiratory Distress Syndrome (ARDS) and its severity were defined according to the Berlin definition [9]. In patients whose partial pressure of oxygen (PaO2) was unavailable; SapO2/FiO2 ratio was used to assess ARDS and severity [10]. Mild ARDS was considered when PaO2/FiO2 ratio was > 200 mmHg or SapO2/FiO2 > 235 mmHg, moderate when PaO2/FiO2 ratio was > 100 mmHg or SapO2/FiO2 > 160 mmHg and severe when PaO2/FiO2 ratio was ≤ 100 mmHg.

Bacterial infection was documented as the presence of one of the following: fever or chills in the absence of other etiologies, purulent sputum, catheter swelling, inflammatory diarrhea or abdominal pain, along with microbiologic results including blood and urine cultures, upper and lower respiratory samples, cerebrospinal fluid, urinary antigen tests, intraoperative samples, glutamate dehydrogenase test or Clostridioides toxin in stool test. Bacterial pathogen evaluation in blood, fluids, sputum and other samples was performed according to standard microbiological procedures during hospital admission. In addition, laboratory parameters (neutrophilia or procalcitonin elevation) along
with radiological and intraoperative findings were considered, particularly in those patients whose microbiological confirmation was not possible. Every suspected infection and its pathogen were carefully and individually assessed by two senior physicians to determine clinical relevance and to avoid selection bias.

Microorganisms were considered multidrug resistant (MDR) if they were resistant to one or more agents in at least three antibiotic classes (beta-lactams, fluoroquinolones, macrolides, aminoglycosides or sulfamides), while difficult-to-treat resistance (DTR) was defined by the resistance to all first-line agents, including all beta-lactams and fluoroquinolones [11, 12].

Statistical analysis

Descriptive analyses were performed through the mean (standard deviation, SD) for quantitative variables and absolute (and relative) frequencies for the categorical. An univariate analysis was performed comparing those characteristics for patients who suffered bacterial infections vs those who did not, and also between survivors and non-survivors by means of chi-square test in case of categorical variables and Mann–Whitney’s U or Student t-test for numerical variables depending on their distributions and performing the Levêne test. Potential confounding variables were entered into two multivariable logistic regression analyses. The objective was to identify factors related with the risk of bacterial infection and mortality, respectively. For all analyses, significance level was defined as a p value below 0.05. Statistical analysis was performed using SPSS software version 26.0 (IBM, Spain).

Results

Patients characteristics

A total of 1594 patients admitted because of suspected or confirmed SARS-CoV-2 pneumonia between March and April 2020 were analyzed. Mean age was 65 years old, 62.1% were male and 87.2% had a positive PCR for SARS-CoV-2 at the time of admission. Overall, 135 patients (8.5%) developed a bacterial infection during admission (Table 1). Patients with infections were significantly older (mean age 68 vs 64.5, p = 0.007) and presented higher rates of baseline

| Table 1 Baseline characteristics of the study population | Total N (%) | Bacterial infections | p value* |
|----------------------------------------------------------|-------------|----------------------|----------|
| COVID-19 hospitalized patients                           | 1594        | 135                  | 1459     | –        |
| Mean age (mean, SD)                                      | 65 (15.0)   | 68 (14.3)            | 64.5 (14.9) | 0.007   |
| Male sex                                                 | 990 (62.1)  | 87 (64.4)            | 903 (61.9) | NS       |
| High blood pressure                                      | 699 (43.9)  | 65 (48.1)            | 634 (43.5) | NS       |
| Diabetes mellitus                                        | 281 (17.6)  | 37 (27.4)            | 244 (16.7) | 0.002    |
| Obesity                                                  | 424 (26.6)  | 36 (30)              | 388 (35.7) | NS       |
| Heart disease                                            | 270 (16.9)  | 28 (20.7)            | 242 (16.6) | NS       |
| Neurological disease                                     | 225 (14.1)  | 28 (20.7)            | 197 (13.5) | 0.021    |
| Lung disease                                             | 248 (15.6)  | 26 (19.3)            | 222 (15.2) | NS       |
| Kidney disease                                           | 112 (7)     | 18 (13.3)            | 94 (6.4)  | 0.003    |
| Liver disease                                            | 48 (3)      | 6 (4.4)              | 42 (2.9)  | NS       |
| Immunosuppression                                        | 166 (10.4)  | 39 (28.9)            | 127 (8.7) | <0.0001  |
| Autoimmune disease                                       | 65 (4.1)    | 12 (8.9)             | 53 (3.6)  | 0.01     |
| Solid organ transplantation                              | 30 (1.9)    | 6 (4.4)              | 24 (1.6)  | 0.036    |
| Hematological disease                                    | 35 (2.2)    | 10 (7.4)             | 25 (1.7)  | 0.000    |
| Solid organ neoplasm                                     | 32 (2)      | 8 (5.9)              | 24 (1.6)  | 0.004    |
| Others                                                   | 4 (0.25)    | –                    | –         | –        |
| Immunosuppressive treatment                              | 139 (8.7)   | 34 (25.2)            | 105 (7.2) | 0.000    |
| Steroids                                                 | 68 (4.3)    | 15 (11.1)            | 53 (3.6)  | 0.000    |
| Calcineurin inhibitors                                   | 25 (1.6)    | 6 (4.4)              | 19 (1.3)  | 0.005    |
| Mycophenolate                                            | 25 (1.6)    | 8 (5.9)              | 17 (1.2)  | 0.000    |
| Biologics                                                | 30 (1.9)    | 6 (4.4)              | 24 (1.6)  | 0.022    |
| Chemotherapy                                             | 16 (1)      | 6 (4.4)              | 10 (0.7)  | 0.000    |
| Others                                                   | 6 (0.4)     | –                    | –         | –        |

SD Standard deviation, NS Non-significant
Comorbidities as diabetes (27.4% vs 16.7%, \( p = 0.002 \)), neurological disease (20.7% vs 13.5%, \( p = 0.021 \)) and kidney disease (13.3% vs 6.4%, \( p = 0.021 \)). In addition, 28.9% of patients with bacterial infection were immunosuppressed (vs 8.7%, \( p < 0.0001 \)), being the main causes: autoimmune disease (8.9%), hematological disease (7.4%), solid organ neoplasm (5.9%) and solid organ transplantation (4.4%). As a result, 25.2% of infected individuals were receiving immunosuppressive treatment.

A total of 156 bacterial infections occurred in 135 patients, with significant microbiological isolation in 91.9% of them (Table 2). The main sites of infection were urinary tract (32.6%), lung (31.8%) and bacteremia (31.9%), related to catheter in 67.4% of them. In addition, nine patients (6.7%) presented intra-abdominal or skin and soft tissue infection. Other foci were meningitis, endocarditis, otorhinolaryngological site, tuberculosis or septic shock (5.9%).

Regarding the observed microorganisms, gram-positive cocci were the most frequent isolation (54.1%). On the other hand, gram-negative bacteria were documented in 40 patients (29.6%) while non-fermentative bacteria were identified in 13 patients (9.6%). Species are also shown in Table 2.

MDR were isolated in 26 patients (19.3%); due to E. Coli spp (30.8%), Pseudomonas (15.4%), resistant staphylococci (15.4%), Stenotrophomonas (15.4%), Enterobacter (7.7%), Klebsiella (7.7%), Achromobacter (3.8%) and Acinetobacter species (3.8%). 63.3% of MDR infections happened in ICU admitted patients. In parallel, Gram-negative-DTR were identified in 18 (13.3%), being E. Coli (27.8%), Stenotrophomonas (22.2%), Pseudomonas (16.7%), Enterobacter (11.1%), Klebsiella (11.1%), Achromobacter (5.5%) and Acinetobacter species (5.5%). 77.8% of these isolates were observed in patients admitted to the ICU.

11 patients had no isolate. Foci were: nosocomial pneumonia (four patients), skin and soft tissue (three patients), urinary tract (two patients), diverticulitis (one patient) and septic shock in an immunosuppressed patient with hematological disease.

**Disease severity, treatment and outcomes.**

Overall, 90.4% of patients with any bacterial infection have had ARDS in the context of COVID-19 disease vs 74.8% of patients without infectious complications (\( p < 0.001 \)). In addition, these patients had lower SapO2/FiO2 ratios (198 vs 280, \( p < 0.001 \)). Consequently, the patients with bacterial infections had more severe ARDS (40.7% vs 5.1%, \( p < 0.001 \)) when compared with the rest. The immunosuppressive treatment used to treat ARSD was also analyzed. Patients with infections had received more steroids (76.1% vs 56.5%, \( p < 0.0001 \)) and more tocilizumab (40% vs 16.9%, \( p < 0.001 \)).

Considering outcomes, patients who had suffered bacterial infection had longer hospital stay (19.5 vs 8.4 days, \( p < 0.001 \)), had been more frequently admitted to the ICU (40% vs 3.8%, \( p < 0.001 \)) and ICU stays had been significantly higher (27.2 vs 10.4 days, \( p < 0.001 \)). In addition, these patients had higher readmission rates after discharge (14.2% vs 4.9%, \( p < 0.001 \)), 57.9% of them motivated by bacterial infections acquired during first admission. Overall mortality was 15.1%, being significantly higher in patients with bacterial infection (25.03% vs 6.70%, \( p < 0.001 \)).

![Springer]
Risk factors for bacterial infection

To identify the risk factors associated with bacterial infections in the context of COVID-19, a multivariable analysis was performed considering the patient’s baseline characteristics, previous treatments, disease severity and the treatment used for ARDS (Table 3). Independent factors related with bacterial infection were: age (OR 1.02, 95% CI 1.01–1.04, \(p\) = 0.009), neurological disease (OR 1.69, 95% CI 1.01–2.82 (\(p\) = 0.046)), immunosuppression (OR 4.41, 95% CI 2.76–7.06, \(p\) < 0.001) and ICU admission (OR 21.36, 95% CI 13.21–34.55, \(p\) < 0.001). Neither steroid nor tocilizumab combined with steroid treatment for ARDS were significantly associated with a higher risk of infection after variable adjustment.

Mortality risk factors

Since a higher proportion of individuals with bacterial infection died during admission in the univariate analysis, a multivariable analysis was performed to identify mortality risk factors (Fig. 1). Mortality was determined by baseline comorbidities, including age (OR 1.13, 95% CI 1.10–1.16, \(p\) < 0.0001), neurological disease (OR 2.77, 95% CI 1.77–4.34, \(p\) < 0.0001), kidney disease (OR 3.46, 95% CI 1.92–6.24, \(p\) < 0.0001), previous immunosuppression (OR 3.33, 95% CI 1.91–5.81, \(p\) < 0.0001) and by the presence and severity of ARDS: mild ARDS (OR 4.67, 95% CI 1.50–14.54, \(p\) = 0.008), moderate ARDS (OR 93.88, 95% CI 29.27–301.08, \(p\) < 0.0001) and severe ARDS (OR 282.10, 95% CI 79.18–1005.33, \(p\) < 0.0001). By contrast, bacterial infections were not independently associated with mortality (OR 0.85, CI 0.47–1.53, \(p\) > 0.05). Steroid treatment (OR 0.35, 95% CI 0.20–0.60, \(p\) < 0.0001) and the combination of steroids with tocilizumab (OR 0.56, 95% CI 0.34–0.93, \(p\) < 0.024) showed lower mortality rates.

Discussion

In this study, we aimed to describe and analyze the burden and risk factors of bacterial infections in patients with COVID-19 disease, since the main therapeutic approaches to date are corticosteroids and tocilizumab, both with recognized potential to develop infections.

We documented a prevalence of 8.5% of bacterial infections, a slightly higher proportion compared to nosocomial and health-care associated infection rates before the pandemic [13, 14]. However, our results are similar to those reported in other COVID-19 cohorts [15, 16]. In addition, we also confirmed that infections are not only caused by respiratory superinfection. There is an important rate of primary and catherer-related bacteremias, urinary tract and abdominal infections, with a significant rate of gram-positive cocci, enterobacterial, non-fermentative and multiresistant pathogens [14, 17, 18]. These are not surprising data since COVID-19 actually can result in long hospital stays, ICU admission, vascular and respiratory devices, malnutrition and a wider use of empirical antibiotherapy, all well-known risk factors for nosocomial infection [19, 20]. Furthermore, SARS-CoV-2 infection could result in a systemic hyperinflammatory disease that carries a state of

Table 3 Risk factors for bacterial infections in COVID-19 hospitalized patients

| Baseline conditions | Univariate analysis* | Multivariate analysis** |
|---------------------|----------------------|------------------------|
| OR (95% CI)         | \(p\) value          | OR (95% CI)            | \(p\) value |
| Age 1.02 (1.01–1.03)| 0.007                | 1.02 (1.01–1.04)       | 0.009      |
| DM 1.88 (1.26–2.81) | 0.002                | 1.60 (0.99–2.49)       | 0.059      |
| Neurological disease 1.68 (1.08–2.60) | 0.022 | 1.69 (1.01–2.82) | 0.046 |
| Kidney disease 2.23 (1.30–3.82) | 0.003 | 1.221 (0.64–2.29) | 0.555 |
| Active neoplasm 2.66 (1.52–4.65) | 0.001 | 1.047 (0.50–2.20) | 0.903 |
| Immunosuppression 4.26 (2.82–6.45) | <0.001 | 4.41 (2.76–7.06) | <0.001 |
| Outcome ARDS 3.17 (1.77–5.68) | <0.001 | 1.34 (0.70–2.55) | 0.375 |
| ICU admission 16.69 (10.80–25.81) | <0.001 | 21.36 (13.21–34.55) | <0.001 |
| Treatment Steroids 2.46 (1.63–3.70) | <0.001 | 0.94 (0.55–1.61) | 0.828 |
| Tocilizumab 3.29 (2.27–4.76) | <0.001 | 0.66 (0.12–3.75) | 0.636 |
| Steroids* + Tocilizumab\(^T\) 2.43 (1.66–3.58) | <0.001 | 1.31 (0.80–2.16) | 0.282 |

Odds ratio, confidence intervals and \(p\) values marked with bold indicate statistically significance

\(OR\) Odds ratio, \(CI\) Confidence interval, \(DM\) Diabetes mellitus, \(ARDS\) Acute respiratory distress syndrome, \(ICU\) Intensive care Unit
\(^T\): Product term between steroids and tocilizumab treatment
immunosuppression beyond lung injury [21, 22], contributing to a significant number of infectious complications affecting other sites.

Our data show that, in addition to age and baseline comorbidities, ICU admission was the main risk factor for the development of bacterial infection. At the same time, ARDS severity and the respiratory worsening of patients during the disease mainly determined ICU admission. Other authors have described significantly higher rates of secondary infections in critically ill patients with severe ARDS [23–25]. Moreover, Bardi et al. identified disease severity as the only factor associated with the development of infection in the ICU [26]. The pandemic situation of the first wave implied a lack of material and staff, infrastructural changes and a significant work overload that altered the normal organization of the ICU. As a result, standards of prophylactic care and aseptic conditions of the procedures were difficult to fulfill as usual, justifying the higher rates of infectious complications.

On the other hand, steroid treatment was initially criticized during the first months of the pandemic since there was no robust evidence to support its use. Several reports informed that early treatment with steroids might extend SARS-CoV-2 RNA replication [27, 28]. In addition, bacterial and opportunistic infections during or after steroid treatment are a major concern and recognized side effect, even at low doses and short courses [6, 29, 30], being a possible limitation for its use in COVID-19 patients. As a matter of fact, Obata et al. found that steroids but not tocilizumab were associated with higher rates of bacterial and fungal infection in COVID-19 hospitalized patients [31]. However, in our cohort neither steroid treatment nor tocilizumab exposure carried a significant risk of bacterial infection when adjusted in the multivariate analysis. Consequently, our study confirms the benefit of the anti-inflammatory effect of steroids in COVID-19, overcoming the potential risk of infections in this scenario [3, 32, 33].

In parallel, similar concerns have affected the use of tocilizumab in autoimmune diseases [7, 34], revealing an even higher risk of bacterial infections with tocilizumab than with tumor necrosis factor inhibitors (TNFi) [35]. In our cohort, tocilizumab use was limited (one or two doses), therefore not conditioning the maintained blockage of IL-6R and avoiding the possible long-term immunosuppression and risk of infection [34]. To note, Stone et al. documented fewer serious infections in patients treated with tocilizumab [4] and the recent trial from Veiga et al. showed no differences in the secondary infection rates when tocilizumab was compared with standard care [5].

Finally, the main related mortality factors were again age, comorbidities and ARDS, while bacterial infections were not an independent factor, reinforcing the hypothesis that infections are a surrogate marker of the most fragile or most severely affected patients with COVID-19. Furthermore, steroid and the combination of steroid with tocilizumab provided a protective effect, supporting its role.

---

**Fig. 1** Predictors of mortality in COVID-19 hospitalized patients. Odds ratio are represented by squares and the lines correspond to 95% confidence interval. *CI* Confidence interval, *ARDS* Acute respiratory distress syndrome, *ICU* Intensive care Unit.

| Variable* | Odds Ratio (95% CI) |
|-----------|---------------------|
| Age (years) | 1.13 (1.11-1.16) |
| Hypertension | 0.99 (0.83-1.56) |
| Diabetes mellitus | 1.49 (0.96-2.31) |
| Heart disease | 1.18 (0.76-1.84) |
| Neurological disease | 2.77 (1.77-4.34) |
| Kidney disease | 3.46 (1.92-6.24) |
| Liver disease | 1.79 (0.88-4.74) |
| Neoplasm | 1.25 (0.57-2.76) |
| Immunosuppression | 3.33 (1.91-5.81) |
| Mild ARDS | 4.67 (1.50-14.54) |
| Moderate ARDS | 93.88 (29.27-301.09) |
| Severe ARDS | 282.10 (79.18-1005.33) |
| Infectious complications | 0.85 (0.47-1.53) |
| ICU admission | 0.33 (0.08-1.38) |
| Only Steroids | 0.35 (0.20-0.61) |
| Only Tocilizumab | 1.29 (0.29-5.74) |
| Steroids + Tocilizumab | 0.56 (0.34-0.93) |

* CI: Confidence interval, ARDS: Acute respiratory distress syndrome, ICU: Intensive care Unit.
in COVID-19, since they did not lead to more bacterial infections.

According to our findings, questions about antibiotic therapy during COVID-19 disease arise again. Others have observed that, to date, there is no evidence enough to support empirical antimicrobial due to data absence [36]. In parallel, our results support that antibiotic prescription should not be generalized and might be carefully evaluated; above all if we consider that infections are the consequence of severe disease. Consequently, the best approach seems to be ARDS treatment with clinical and microbiological surveillance; waiting to microbiological definite diagnosis rather than early empirical prescription when suspected.

The main limitation of our study was the absence of data regarding the empirical and targeted antibiotic treatment in the cohort. We were not able to understand their role in the risk and courses of bacterial infections. Unfortunately, and despite that treatment during this period of the pandemic was carefully standardized; no information, conclusions or recommendations could be elucidated in this regard.

In summary, nearly 9% of individuals hospitalized with COVID-19 developed bacterial infection during the first pandemic wave. Although this population exhibited an unfavorable clinical profile, bacterial infections were not independently associated with increased mortality rates or with steroid and tocilizumab treatment for ARDS. This result suggests that bacterial infections reflect disease severity rather than contribute to mortality. Immunosuppressive treatment should be used when indicated given that it did not imply higher bacterial infection rates and resulted beneficial for survival.

Acknowledgements We thank the members of the Puerta de Hierro patients with SARS-CoV-2 pneumonia in terms of survival.

We thank the members of the Puerta de Hierro pandemic wave. Although this population exhibited an unfavorable clinical profile, bacterial infections were not independently associated with increased mortality rates or with steroid and tocilizumab treatment for ARDS. This result suggests that bacterial infections reflect disease severity rather than contribute to mortality. Immunosuppressive treatment should be used when indicated given that it did not imply higher bacterial infection rates and resulted beneficial for survival.

Funding This work has been supported by a grant from Instituto de Salud Carlos III (Expedient number P16-01480).

Availability of data and material The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability Stata v16 software (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC).

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The study was approved by the Research Ethics Committee of our center.

Consent to participate and for publication Consent was requested for all patients to include their clinical information within a database for epidemiological and clinical studies.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. WHO. Coronavirus Disease 2019 Situation Report 62- 5th July 2021 [Internet]. Vol. 2019, WHO Bulletin. 2021. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

2. Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science 368:473–474

3. RECOVERY Collaborative Group, Horby P, Lim WS, Emerson JR, Mafham M, Bell JL, Linsell L et al (2021) Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 384:693–704

4. Stone JH, Frigaud MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, BACC Bay Tocilizumab Trial Investigators et al (2020) Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 383:870–878

5. Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK et al (2021) Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 372:n84

6. George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L et al (2020) Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. Ann Intern Med 173:870–878

7. Morel J, Constantin A, Baron G, Dernis E, Filpo RM, Rist S et al (2017) Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford) 56:1746–1754

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The study was approved by the Research Ethics Committee of our center.

Consent to participate and for publication Consent was requested for all patients to include their clinical information within a database for epidemiological and clinical studies.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. WHO. Coronavirus Disease 2019 Situation Report 62- 5th July 2021 [Internet]. Vol. 2019, WHO Bulletin. 2021. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

2. Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science 368:473–474

3. RECOVERY Collaborative Group, Horby P, Lim WS, Emerson JR, Mafham M, Bell JL, Linsell L et al (2021) Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 384:693–704

4. Stone JH, Frigaud MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, BACC Bay Tocilizumab Trial Investigators et al (2020) Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 383:870–878

5. Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK et al (2021) Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 372:n84

6. George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L et al (2020) Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. Ann Intern Med 173:870–878

7. Morel J, Constantin A, Baron G, Dernis E, Filpo RM, Rist S et al (2017) Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford) 56:1746–1754
20. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Nicollet B, Safdar N, Maki DG (2002) The commonality of risk factors for nosocomial bacterial infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 26:1622–1629
21. Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X et al (2020) Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect 9:1958–1964
22. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281
23. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI) et al (2018) Difficult-to-treat resistant gram-negative bacteremia at 173 US Hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis 67:1803–1814
24. Sikora A, Zahra F. Nosocomial infections. 2020 Jul 6. StatPearls. StatPearls Publishing, Treasure Island (FL)
25. Lansbury L, Lim B, Baskaran V, Lim WS (2020) Co-infections in hospitalized patients with COVID-19: a retrospective cohort study. Ann Rheum Dis 78:456–464
26. Zhang H, Zhang Y, Wu J, Li Y, Tao Y et al (2020) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan. China Clin Infect Dis 71:762–768
27. Leisman DE, Deutschman CS, Legrand M (2020) Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and disregulated inflammation. Intensive Care Med 46:1105–1108
28. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR et al (2020) Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 36:233–13319
29. Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954–963
30. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM et al (2017) Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 357:j1415
31. Obata R, Maeda T, Rizk D, Kuno T (2021) Increased Secondary Infection in COVID-19 Patients Treated with Steroids in New York City. Jpn J Infect Dis 74:307–315
32. Griffin DO, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L et al (2021) The importance of understanding the stages of COVID-19 in treatment and trials. AIDS Rev 23:40–47
33. Ngo BT, Mark P, Kory P, Shapiro L, Thomasset R, Iglesias J et al (2021) The time to offer treatments for COVID-19. Expert Opin Investig Drugs 30:505–518
34. Gron KL, Arkema EV, Glinthorn B, Mehnert F, Østergaard M, Dreyer L, ARTIS Study Group et al (2019) Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis 78:320–327
35. Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S et al (2019) Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis 78:456–464
36. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M et al (2020) Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 71:2459–2468

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.